Background {#Sec1}
==========

Toll-like receptors (TLRs) are members of a membrane receptor protein family that recognize the antigenic determinants of viruses, bacteria, protozoa, and fungi, and are thus associated with immunity. There are two pathways associated with the immune deficiencies that lead to disease: the MyD88-IRAK4 pathway, involving all TLR family proteins except TLR3, and the TLR3-Unc93b-TRIF-TRAF3 pathway \[[@CR1], [@CR2]\]. Therefore, TLR3 can be considered a unique protein in the TLR family, and it has been further implicated in the development of tumors resulting from an activated immune system.

*TLR3* single nucleotide polymorphisms (SNPs) could possibly affect cancer susceptibility and could therefore serve as potential biomarkers to evaluate cancer risk \[[@CR3]\]. Thus, *TLR3* polymorphisms that are associated with both heredity and environmental factors may be critical in bridging the relationship between genetic factors and external environmental conditions. *TLR3* SNPs were originally identified by *He* et al. \[[@CR4]\] in 2007. Since then, several studies have focused on examining the association of *TLR3* SNPs with cancer risk. However, the first studied SNP site included 10 SNPs covering the entire *TLR3* gene, and because each of these SNPs had several reported names, confusion arose in the literature. Furthermore, published results of the *TLR3* gene have been conflicting. The *TLR3* SNPs that exhibit the most variability are rs3775290 and rs3775291; however, their relationship with cancer risk remains unclear. For instance, although the majority of studies have reported that the rs3775290 variant T allele was associated with an increased cancer risk (odds ratio \[OR\] \> 1), four studies testing this conclusion did not reach statistical significance (*P* \> 0.05) \[[@CR5]--[@CR8]\] and only one additional study produced significant results (*P* \< 0.05) \[[@CR9]\]. Furthermore, another study reported the opposite result that the variant allele was associated with a decreased cancer risk (OR = 0.88) \[[@CR4]\]. Thus, a comprehensive analysis integrating all studies on *TLR3* SNPs and cancer risk is needed. In addition, no systematic review or meta-analysis for the *TLR3* gene polymorphisms has been performed.

Here, we systematically reviewed published data and comprehensively analyzed and integrated all published studies on the relationship between *TLR3* SNPs and cancer risk. We also contacted the authors of these studies to obtain any data that was omitted from published articles so as to enhance our comprehension of the details surrounding these SNPs. We included a meta-analysis for hotspot SNPs (rs3775290, rs3775291, rs3775292, and rs5743312) that have been described in at least three published studies to enhance the comprehensiveness of our assessment into the association between *TLR3* SNPs and cancer risk.

Methods {#Sec2}
=======

Publication search {#Sec3}
------------------

A systematic literature search was performed on the association between the *TLR3* rs3775290, rs3775291, rs3775292, rs5743312 polymorphisms and cancer risk. Our final search concluded with literature published on or before October 5th, 2014. Two independent researchers (Ben-Gang Wang and De-Hui Yi) searched the PubMed, Chinese National Knowledge Infrastructure (CNKI), and Web of Science databases for the following keywords: "*TLR3*," "cancer/carcinoma/tumor/neoplasm," and "polymorphism". The inclusion criteria were as follows: (1) case-control studies, (2) studies evaluating the association between *TLR3* polymorphisms and cancer risk, and (3) the SNP was reported in at least 3 publications. The major exclusion criteria were as follows: (1) studies that presented duplicate data, (2) studies that included only cancer patients (i.e., no healthy controls), and (3) studies that investigated benign diseases compared with controls.

Data extraction {#Sec4}
---------------

Two independent researchers (Ben-Gang Wang and De-Hui Yi) each extracted all data that were considered to be relevant, and in cases of inconsistent selection, a third author (Yong-Feng Liu) participated in data selection. In this way, a consensus was reached on which studies should be included for analysis. For each study, the following items were collected: first author's name, publication year, country of origin, ethnicity, cancer type, source of control groups (population- or hospital-based), genotyping method, total numbers of cases and controls, and genotype distributions in cases and controls. When we considered the published data to be insufficient for our analyses, we contacted the authors to obtain the original data. Thus, the data included in this review were obtained from both published and unpublished studies.

Statistical analyses {#Sec5}
--------------------

The Chi-square test was used to determine the Hardy-Weinberg equilibrium (HWE) for the genotype frequencies of different *TLR3* polymorphisms; a result of *P* \< 0.05 was considered to indicate significant disequilibrium. The strength of the association between *TLR3* polymorphisms and cancer risk was calculated using odds ratios (ORs) with 95 % confidence intervals (CIs). The heterogeneity between different studies was calculated using the Cochran's *Q* test and quantified by the *I*^*2*^ (a significance level of *P* \< 0.10). When heterogeneity did not exist, a fixed-effect model based on the Mantel-Haenszel method was used to assess the pooled OR of each study \[[@CR10]\]. When heterogeneity did exist, a random-effect model based on the method developed by DerSimonian and Laird was employed \[[@CR11]\]. Five comparison models were evaluated: heterozygote comparison (M1: Aa vs. AA), homozygote comparison (M2: aa vs. AA), dominant model (M3: Aa + aa vs. AA), recessive model (M4: aa vs. AA + Aa), and allelic model (M5: a vs. A). "A" indicates wild allele, and "a" indicates variant allele. OR~1~ and OR~2~ were calculated for the genotypes aa vs. AA (M2) and Aa vs. AA (M1), and were used to determine the most appropriate genetic model. According to the reference \[[@CR12]\], a recessive model is recommended in cases where OR~1~ ≠ 1 and OR~2~ = 1, whereas a dominant model is suggested for cases in which OR~1~ = OR~2~ ≠ 1, and a codominant model is indicated if OR~1~ \> OR~2~ \> 1 or OR~1~ \< OR~2~ \< 1.

For studies with sufficient patients, we also performed stratification analyses on cancer type, ethnicity (Asian or Caucasian), sources of controls (population- or hospital-based study design), and sample size (total samples ≥1000 \[large sample size\] or \<1000 \[small sample size\]). The Begg's rank correlation and the Egger's linear regression tests were used to evaluate publication bias \[[@CR13], [@CR14]\]. A value of *P* \< 0.10 was considered statistically significant. All analyses were performed using STATA software, version 11.0 (STATA Corp., College Station, TX, USA).

Results {#Sec6}
=======

Characteristics of the included studies {#Sec7}
---------------------------------------

Searches of the PubMed, CNKI, and Web of Science databases using different combinations of our keywords yielded a total of 155 records (after duplicates were removed). We excluded 50 studies based on the information presented in the title or abstract (17 were irrelevant articles, 16 were functional studies rather than polymorphism studies, and 17 were review articles) and 91 studies based on the information presented in the text (5 were not case-control studies, 62 were not about *TLR3* gene polymorphisms, and 24 were not relevant to cancer). Thus, a total of 14 case-control studies that met our inclusion criteria were included in our systematic review and final meta-analysis, which consisted of 7997 cancer patients and 8699 cancer-free controls \[[@CR4]--[@CR9], [@CR15]--[@CR22]\] (Table [1](#Tab1){ref-type="table"}).Table 1The studies included in this systematic review for the association between Toll-like receptor 3 (*TLR3*) single nucleotide polymorphisms (SNPs) and the risk of developing cancerPublication yearStudyCountrySample sizeSource of controlsGenotyping methodMatched factorsAdjusted factorsCasesControls2007He *et al.* \[[@CR4]\]China434512Population-basedSequencingSex and age matchedNone2009Etokebe *et al.* \[[@CR8]\]Croatia130101Population-basedqPCRAll females, age not matchedNone2010Lei *et al.* \[[@CR15]\]China9811221Population-basedSNP StreamAll females, age matchedAge and BMI2011Pandey *et al.* \[[@CR7]\]India200200Not mentioned, only healthy controlsPCR-RFLPAll females, age matchedAgeGast *et al.* \[[@CR16]\]Germany763736Hospital-basedTwo multiplex PCRSex not mentioned, age not matchedNone2012Mandal *et al.* \[[@CR6]\]India195250Hospital-basedPCR-RFLPAll males, age matchedSlattery *et al*.\[[@CR17]\]USA23092915Population-basedMultiplexed bead arraySex and age matchedNone2013Singh *et al.* \[[@CR5]\]India200200Hospital-basedPCR-RFLPSex and age matchedAge, sex, and smokingLi *et al.* \[[@CR9]\]China466482Population-basedPCR-RFLPSex and age matchedSex and ageResler *et al.* \[[@CR18]\]USA840800Population-basedChipAll females, age matchedAgeZeljic *et al.* \[[@CR19]\]Yugoslavia93104Not mentioned, only healthy controlsqPCRSex and age matchedSex, age, smoking, and alcohol consumptionYeyeodu *et al.* \[[@CR20]\]USA10272Hospital-basedSNP StreamAll females, age not mentionedNoneMoumad *et al.* \[[@CR21]\]Germany472362Hospital-basedKASParSex and age matchedSex and age2014Zidi *et al.* \[[@CR22]\]Tunisia130200Hospital-basedPCR-RFLPAll females, age not matchedNoneqPCR, quantitative polymerase chain reaction; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; KASPar, KASPar SNP genotyping system; BMI, body mass index.

Of the 14 enrolled studies, all but 4 were matched by age; 6 were sex-matched, 1 did not mention the sex-matching, and 7 that examined either breast, cervical, or prostate cancer did not need to match for sex. Six studies investigated Asians, 7 investigated Caucasians, and 1 was conducted in Africa. The controls were hospital-based in 6 studies, population-based in 6 studies, and not mentioned in 2 studies. Genotyping methods included polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP, 5 studies), quantitative polymerase chain reaction (qPCR, 2 studies), Chip (1 study), multiplexed bead array (1 study), two multiplex PCR (1 study), the KASPar SNP genotyping system (1 study), SNP Stream (2 studies), and sequencing (1 study). Eight studies checked genotypes for quality control \[[@CR4]--[@CR6], [@CR9], [@CR16]--[@CR18], [@CR21]\]. The genotype distribution of controls was consistent with the Hardy-Weinberg equilibrium model in all but four studies \[[@CR9], [@CR15], [@CR17], [@CR22]\].

In these 14 studies, 12 SNPs were reported. Table [2](#Tab2){ref-type="table"} lists the SNP locations, studied tumor types, and any associations between *TLR3* SNPs and cancer risk. In summary, there are 10 types of cancer that have been evaluated in relation to *TLR3* SNPs. The majority of the 12 SNPs located within an intronic region of the *TLR3* gene, except for 2 that were found in the 3′ and 5′ regions of the gene and another 2 that located within exons. Only 4 SNPs (rs3775290, rs3775291, rs3775292, and rs5743312) were reported in at least 3 studies. For this reason, we defined them as hotspot SNPs which covered all 10 cancer types included in this study (Table [3](#Tab3){ref-type="table"}).Table 2The associations between *TLR3* polymorphisms and cancer risk in the 14 selected studies*TLR3* SNPLocationAssociation(s) with tumor(s)rs100254053′-near geneBreast cancer, associated \[[@CR20]\]rs11721827Intron 1Nasopharyngeal carcinoma, associated \[[@CR4]\]Colorectal cancer, associated \[[@CR17]\]rs11730143Intron 1Melanoma, not associated \[[@CR16]\]rs13126816Intron 1Melanoma, not associated \[[@CR16]\]rs3775290Exon 4Nasopharyngeal carcinoma, not associated \[[@CR4]\]Bladder cancer, not associated \[[@CR5]\]Prostate cancer, not associated \[[@CR6]\]Cervical cancer, not associated \[[@CR7]\]Breast cancer, not associated \[[@CR8]\]Cervical cancer, associated \[[@CR22]\]rs3775291Exon 4, L412FNasopharyngeal carcinoma, not associated \[[@CR4]\]Hepatocellular carcinoma, associated \[[@CR9]\]Breast cancer, not associated \[[@CR15]\]Melanoma, not associated \[[@CR16]\]Colorectal cancer, not associated \[[@CR17]\]Breast cancer, not associated \[[@CR18]\]Oral cancer, associated \[[@CR19]\]Nasopharyngeal carcinoma, associated \[[@CR21]\]rs3775292Intron 3Melanoma, not associated \[[@CR16]\]Colorectal cancer, associated \[[@CR17]\]Breast cancer, not associated \[[@CR18]\]rs57433055′-near geneHepatocellular carcinoma, not associated \[[@CR9]\]Colorectal cancer, not associated \[[@CR17]\]rs5743312Intron 3Nasopharyngeal carcinoma, not associated \[[@CR4]\]Melanoma, not associated \[[@CR16]\]Oral cancer, associated with survival \[[@CR19]\]rs7657186Intron 1Melanoma, not associated \[[@CR16]\]Breast cancer, not associated \[[@CR20]\]rs7668666Intron 3Melanoma, not associated \[[@CR16]\]Table 3Characteristics of the 14 studies included for this meta-analysisStudyEthnicityCancer typeSample sizeCasesControls*P* of HWECaseControlwt/wtwt/varvar/varwt/wtwt/varvar/varrs3775290 (C13766T, C \> T) He *et al*. \[[@CR4]\]AsianNasopharyngeal carcinoma395371565^\*^225^\*^510^\*^232^a^ Singh *et al*. \[[@CR5]\]AsianBladder cancer20020010681131227170.391 Mandal *et al*. \[[@CR6]\]AsianProstate cancer19525011568121578490.585 Pandey *et al*. \[[@CR7]\]AsianCervical cancer2002009198111108190.217 Etokebe *et al*. \[[@CR8]\]CaucasianBreast cancer130101585614464280.713 Zidi *et al*. \[[@CR22]\]CaucasianCervical cancer13020069481376106180.026rs3775291 (G13909A, L412F, G \> A) He *et al*. \[[@CR4]\]AsianNasopharyngeal carcinoma333287405^\*^261^\*^359^a^215^a^ Li *et al*. \[[@CR9]\]AsianHepatocellular carcinoma46648219222252256203230.030 Lei *et al*. \[[@CR15]\]AsianBreast cancer98112214474311035945001270.155 Gast *et al*. \[[@CR16]\]CaucasianSkin malignant melanoma73266837929162332284520.415 Slattery *et al*. \[[@CR17]\]CaucasianColon cancer155419557486531539478171910.446Rectal cancer754959**363332**59**478381**1000.066 Resler *et al*. \[[@CR18]\]CaucasianBreast cancer84080142734865418318650.679 Zeljic *et al*. \[[@CR19]\]CaucasianOral squamous cell carcinomas93104393915435380.128 Moumad *et al*. \[[@CR21]\]AfricanNasopharyngeal carcinoma4723622891701325296140.210rs3775292 (C/G, intron 3, C \> G) Gast *et al*. \[[@CR16]\]CaucasianSkin malignant melanoma73066846423333413228270.521 Slattery *et al*. \[[@CR17]\]CaucasianColon cancer15541956**990507**57**1253601**1020.008Rectal cancer754959494**22238**586**33538**0.247 Resler *et al*. \[[@CR18]\]CaucasianBreast cancer84080052228434509262290.507rs5743312 (C9948T, intron 3, C \> T) He *et al*. \[[@CR4]\]AsianNasopharyngeal carcinoma405200640^\*^170^a^316^\*^84^a^ Lei *et al*. \[[@CR15]\]AsianBreast cancer996124558234866770433420.044 Gast *et al*. \[[@CR16]\]CaucasianSkin malignant melanoma71665750020016453193110.060 Zeljic *et al*. \[[@CR19]\]CaucasianOral squamous cell carcinomas9310469213782420.923wt/wt, wild type/wild type, indicating wild genotype; wt/var, wild type/variant type, indicating heterozygote; var/var, variant type/variant type, indicating variant genotype; HWE, Hardy-Weinberg equilibrium. ^\*^Only the data of allelic model were available, and thus the studies were analyzed only when the allelic model was used. The bold means the genotype information of the rs3775291 and rs3775292 SNPs that readers could not found in \[[@CR17]\], and these data were kindly provided by the contacted authors.

Unpublished data obtained from the original authors {#Sec8}
---------------------------------------------------

Slattery *et al*. \[[@CR17]\] detected *TLR3* rs3775291 and rs3775292 SNPs in colorectal cancer patients and showed only the minimum allele frequency for these SNPs. We contacted the authors of this study to obtain the genotype information of these two SNPs that were found in the case and control groups, and we were especially interested in the results when dividing patients into colon cancer and rectal cancer groups. These results are presented in bold in Table [3](#Tab3){ref-type="table"}.

Quantitative synthesis {#Sec9}
----------------------

The variant T allele of the rs5743312 SNP was significantly associated with an increased risk of cancer when compared with the wild C allele (OR = 1.11, 95 % CI = 1.00--1.24, *P* = 0.047) (Table [4](#Tab4){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}a). The OR~1~ and OR~2~ values of this rs5743312 SNP were 1.88 (*P* \< 0.001) and 1.02 (*P* = 0.832), respectively. Thus, a codominant model (M2) was the most appropriate choice for rs5743312. Regardless of the genetic model, no other *TLR3* SNPs (rs3775290, rs3775291, and rs3775292) were found to be associated with cancer risks.Table 4Pooled ORs and 95 % CIs of *TLR3* polymorphisms in this meta-analysisSNPNumber of studiesM1M2M3M4Number of studiesM5OR (95 % CI)*PI* ^*2*^ (%)OR (95 % CI)*P*I^2^ (%)OR (95 % CI)*P*I^2^ (%)OR (95 % CI)*P*I^2^ (%)OR (95 % CI)*P*I^2^ (%)rs3775290 (C13766T, C \> T)51.040.854^\*^70.01.380.1100.01.090.640^\*^69.41.410.0820.061.060.55059.3(0.72-1.49)(0.93-2.06)(0.77-1.53)(0.96-2.08)(0.87-1.30)rs3775291 (G13909A, L412F, G \> A)81.120.056^\*^53.91.130.335^\*^66.51.120.054^\*^58.61.080.507^\*^65.291.090.064^\*^59.5(1.00-1.26)(0.88-1.45)(1.00-1.26)(0.86-1.37)(1.00-1.19)rs3775292 (C/G, intron 3, C \> G)40.960.554^\*^54.50.930.50034.70.970.47623.10.940.55449.940.970.4160.0(0.83-1.11)(0.75-1.15)(0.89-1.06)(0.76-1.16)(0.90-1.05)rs5743312 (C9948T, intron 3, C \> T)31.020.8320.0**1.88\<0.001**0.01.080.2670.0**1.86\<0.001**0.04**1.110.047**7.1(0.88-1.17)**(1.33-2.67)**(0.94-1.23)**(1.32-2.63)(1.00-1.24)**OR, odds ratio; CI, confidence interval. ^\*^The heterogeneity exists; a random-effect model based on the DerSimonian and Laird method or a fixed-effect model based on the Mantel-Haenszel method was used. M1: Aa vs. AA, heterozygote comparison; M2: aa vs. AA, homozygote comparison; M3: Aa + aa vs. AA, dominant model; M4: aa vs. AA + Aa, recessive model; M5: a vs. A, allelic model (A indicates wild allele, a indicates variant allele). The bold means the significant results.Fig. 1Forest plot of the odds ratios (ORs) for the association of Toll-like receptor 3 (*TLR3*) single nucleotide polymorphisms (SNPs) with cancer risk. **a**, the association of the *TLR3* rs5743312 SNP with cancer risk when stratified by ethnicity (allelic model). **b**, the association of the *TLR3* rs3775290 SNP with cancer risk when stratified by ethnicity (dominant model). **c**, The association of *TLR3* rs3775291 SNP with cancer risk (dominant model) when stratified by cancer type (c1), ethnicity (c2), source of controls (c3), and sample size (c4). \*The cancer type was colon cancer; ^\#^the cancer type was rectal cancer

In the stratified analysis, the rs3775290 variant genotype was significantly associated with an increased cancer risk in Asian populations in M1 (CT vs. CC: OR = 1.28, 95 % CI = 1.02--1.62, *P* = 0.036), M2 (TT vs. CC: OR = 1.79, 95 % CI = 1.05--3.05, *P* = 0.032), and M3 models (CT + TT vs. CC: OR = 1.33, 95 % CI = 1.06--1.67, *P* = 0.013) (Table [5](#Tab5){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}b). For the rs3775291 SNP, both the GA heterozygote and the GA + AA genotypes were consistently associated with an increased risk of nasopharyngeal cancer (GA vs. GG: OR = 1.54, 95 % CI = 1.14--2.09, *P* = 0.005; GA + AA vs. GG: OR = 1.45, 95 % CI = 1.09--1.94, *P* = 0.012) (Table [5](#Tab5){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}c1). When the data were stratified by ethnicity, the GA heterozygote was significantly associated with an increased cancer risk in the Asian subgroup (GA vs. GG: OR = 1.27, 95 % CI = 1.00--1.60, *P* = 0.048) (Table [5](#Tab5){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}c2). When the data were stratified by the source of controls, the hospital-based subgroup showed that the variant allele was significantly associated with an increased cancer risk (GA vs. GG: OR = 1.50, 95 % CI = 1.23--1.83, *P* \< 0.001; GA + AA vs. GG: OR = 1.54, 95 % CI = 1.27--1.87, *P* \< 0.001; A vs. G: OR = 1.43, 95 % CI = 1.23--1.67, *P* \< 0.001) (Table [5](#Tab5){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}c3). Finally, when the data were stratified by sample size, the small sample size subgroup showed that the variant genotype was significantly associated with an increased cancer risk (AA vs. GG: OR = 2.77, 95 % CI = 1.75--4.39, *P* \< 0.001; AA vs. GA + GG: OR = 2.46, 95 % CI = 1.58--3.83, *P* \< 0.001) (Table [5](#Tab5){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}c4).Table 5Pooled ORs and 95 % CIs of *TLR3* polymorphisms in the stratified analysisStratificationNumber of studiesM1M2M3M4Number of studiesM5OR (95 % CI)*PI* ^2^ (%)OR (95 % CI)*PI* ^2^(%)OR (95 % CI)*PI* ^2^(%)OR (95 % CI)*PI* ^2^(%)OR (95 % CI)*PI* ^2^(%)rs3775290 (C13766T, C \> T) Ethnicity  Asian3**1.280.036**0**1.790.032**0**1.330.013**01.610.08041.140.25^a^58.2**(1.02-1.62)(1.05-3.05)(1.06-1.67)**(0.95-2.71)(0.91-1.43)  Caucasian20.720.37275.51.000.99600.760.45^a^75.61.350.52020.890.60^a^63.6(0.34-1.49)(0.55-1.82)(0.38-1.54)(0.54-3.36)(0.58-1.38) Cancer type  Genital system neoplasms40.970.892751.260.301.040.73^a^73.91.330.201.070.64^a^58.8(0.62-1.53)(0.81-1.95)(0.84-1.29)(0.87-2.03)(0.82-1.39) Source of controls  Hospital-basedNANANANA51.120.32^a^54.7(0.90-1.40)  Population-basedNANANANA10.880.23(0.70-1.09)rs3775291 (G13909A, L412F, G \> A) Cancer type  Digestive tract cancer31.160.132^a^65.41.280.42989.11.180.18680.41.180.559^a^87.431.140.288^a^87.5(0.96-1.41)(0.69-2.38)(0.92-1.51)(0.68-2.05)(0.90-1.44)  Breast cancer21.110.11801.040.73901.100.14800.990.911021.050.2880(0.97-1.27)(0.70-1.55)(0.97-1.25)(0.79-1.23)(0.96-1.16)  Nasopharyngeal carcinoma1**1.540.005**0.810.593**1.450.012**0.700.3721.160.0830**(1.14-2.09)**(0.37-1.76)**(1.09-1.94)**(0.33-1.52)(0.98-1.37) Ethnicity  Caucasian51.020.61300.980.784.61.020.73200.970.68540.951.000.940(0.94-1.12)(0.84-1.14)(0.93-1.11)(0.84-1.13)(0.93-1.07)  Asian2**1.270.048** ^**a**^541.760.27291.21.330.10580.71.550.33489.531.210.108^a^79.5**(1.00-1.60)**(0.64-4.82)(0.94-1.89)(0.64-3.77)(0.96-1.53)  African1**1.230.005**0.810.593**1.450.012**0.700.3711.270.062**(1.06-1.43)**(0.37-1.76)**(1.09-1.94)**(0.33-1.52)(0.99-1.63) Source of controls  Hospital-based2**1.50\<0.001**01.610.466^a^86.8**1.54\<0.001**01.370.616^a^86.32**1.43\<0.001**32.6**(1.23-1.83)**(0.45-5.84)**(1.27-1.87)**(0.40-4.76)**(1.23-1.67)**  Population-based61.050.25901.000.99901.040.33800.980.74826.971.020.465^a^0(0.97-1.14)(0.87-1.15)(0.96-1.12)(0.86-1.12)(0.97-1.08) Sample size  Large51.050.21800.980.82301.040.32800.960.545051.020.6290(0.97-1.14)(0.86-1.13)(0.96-1.12)(0.84-1.10)(0.96-1.08)  Small3**1.41\<0.001**45.61.760.184^a^73.7**1.47\<0.001**21.11.630.242^a^73.94**1.30\<0.001**47.9**(1.16-1.70)**(0.77-4.05)**(1.23-1.76)**(0.72-3.65)**(1.15-1.47)**rs3775292 (intron 3, C \> G) Cancer type  Colorectal cancer20.930.609^a^82.20.890.657^a^680.930.464^a^63.80.920.797^a^78.220.940.2330(0.69-1.25)(0.54-1.48)(0.76-1.13)(0.50-1.69)(0.86-1.04)  Breast Cancer11.060.6011.140.6071.070.5351.120.65611.060.499(0.86-1.30)(0.69-1.90)(0.87-1.30)(0.68-1.86)(0.90-1.26)  Skin malignant melanoma10.910.4111.090.7530.930.5031.120.65910.960.683(0.73-1.14)(0.64-1.84)(0.75-1.15)(0.67-1.89)(0.80-1.16)rs5743312 (C9948T, intron 3, C \> T) Ethnicity  AsianNANANANA2**1.170.017**25.3**(1.03-1.33)**  CaucasianNANANANA20.990.9950(0.83-1.21) Sample size  Large21.020.820**1.89\<0.001**41.080.26837.2**1.870.001**021.110.305^a^61.7(0.88-1.17)**(1.32-2.70)**(0.94-1.24)**(1.31-2.65)**(0.99-1.24)  Small10.990.971.700.5691.040.91.700.56621.020.8940(0.51-1.93)(0.28-10.45)(0.55-1.98)(0.28-10.40)(0.78-1.32)NA, not available. Other footnotes as in Table [4](#Tab4){ref-type="table"}. The bold means the significant results.

Heterogeneity {#Sec10}
-------------

The heterogeneities that originated within the collection of selected studies and within each subgroup of studies are shown in Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}, respectively. Slight heterogeneities were found when comparing different studies. To explore the influence of individual studies on the pooled results, we analyzed the sensitivity of our methodology by removing one study at a time from the pooled analyses. No significant heterogeneity was found for any genetic model, which suggested that our results were relatively reliable.

Publication bias {#Sec11}
----------------

The Begg's rank correlation and Egger's linear regression tests were conducted to evaluate publication bias. According to the results of these tests, a slight publication bias for rs3775290 in M2 was indicated (Table [6](#Tab6){ref-type="table"}).Table 6The results of Begg's and Egger's test for the publication biasComparison modelBegg's testEgger's test*Z* value*P* value*t* value*P* valuers3775290 (C13766T, C \> T) M1−0.980.327−0.880.443 M20.980.3273.080.054 M3−0.980.327−0.780.493 M41.470.1421.70.188 M5−0.190.8510.870.432rs3775291 (G13909A, L412F, G \> A) M10.490.6210.620.559 M20.990.3221.060.329 M30.490.6211.020.346 M40.990.3221.020.348 M51.250.2111.480.183rs3775292 (C/G, intron 3, C \> G) M1−1.360.174−1.140.371 M20.001.0003.880.061 M30.001.000−0.680.567 M40.001.0003.110.090 M50.680.4970.140.901rs5743312 (C9948T, intron 3, C \> T) M1−0.520.602−0.390.764 M2−0.520.602−0.760.587 M3−0.520.6020.750.590 M4−0.520.602−0.750.589 M50.001.000−0.860.479NA, not available. Other footnotes as in Table [4](#Tab4){ref-type="table"}.
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In this meta-analysis, we found that *TLR3* rs5743312 was associated with an increased overall risk of developing cancer. This was also true for the large sample size subgroup. *TLR3* rs3775290 and rs3775291 polymorphisms were found to be associated with increased cancer risks in the stratified analysis, whereas no association was found between *TLR3* rs3775292 and cancer risk.

The *TLR3* rs5743312 polymorphism is located in intron 3, and no previous studies have shown any association between this polymorphism and cancer risk. However, after data integration, we concluded that this SNP is the only significant site in the *TLR3* gene with respect to cancer risk. According to our meta-analysis, the remaining 3 SNPs exhibited no association with cancer risks. The subgroup analyses for the rs5743312 SNP showed the same tendency as the whole group analysis. Previous studies have suggested that intronic SNPs may exhibit specific functions, such as directing alternative splicing \[[@CR23], [@CR24]\]. As intronic polymorphisms have been shown to exhibit critical functions, it would be prudent to include intronic SNPs, such as rs5743312, in future studies.

rs3775290 is located in exon 4 of the *TLR3* gene and is also a hotspot *TLR3* SNP. In our stratification analyses, *TLR3* rs3775290 was found to be associated with cancer risk in Asian populations. This may be due to the variability in genetic background between Asians and Caucasians (Fig. [2](#Fig2){ref-type="fig"}). In the HapMap database, rs3775290 showed a ratio of 0.217:0.783 for the wild-type A:variant G allele in the HapMap-CEU population and of 0.408:0.592 for the A:G allele in the HapMap-CHB and HapMap-JPT populations (<http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3775290>). Variations in ethnic backgrounds play an important role in genetic susceptibility, and genetic differences between Asians and Caucasians may be the reason that these different ethnic populations follow different life styles and are thus exposed to different environmental factors \[[@CR25]\]. Population groups that are carrying different genotypes or allele frequencies of the rs3775290 polymorphism may show differences in cancer susceptibility \[[@CR26]\]. The C to T variant of rs3775290 results in a silent mutation in phenylalanine residue 459. When a SNP leads to a silent mutation, it does not necessarily indicate that the SNP has no impact on protein dynamics. For example, a silent mutation located in an exon might affect interactions between genetic elements and additional molecules, such as metal ions or transcription factors \[[@CR27]\].Fig. 2The linkage disequilibrium plot of *TLR3* gene polymorphisms found in individuals of different ethnicities, expanding 20 kb from 5′ to 3′ each (downloaded from the HapMap database). **a**, European; **b**, Chinese Han; **c**, Japanese; **d**, African. Different SNP distributions arise in response to differences in ethnicity. Therefore, differences in ethnicity should be considered when designing the study. Furthermore, some *TLR3* SNPs might be in linkage disequilibrium, suggesting that a haplotype study may be more effective for predicting or screening susceptible populations

To date, the rs3775291 polymorphism has been the most investigated SNP in *TLR3*. In the stratified analysis, *TLR3* rs3775291 was also found to be associated with cancer risk in Asians in a heterozygote model (Table [5](#Tab5){ref-type="table"}). Furthermore, when examining our findings on a subgroup-by-subgroup basis, we found that the small sample size subgroup showed that rs3775291 was associated with a significantly increased cancer risk in the M2 and M4 models, whereas the hospital-based subgroup showed this association in the M1, M3, and M5 models. These findings may have arisen because the 3 corresponding studies each obtained significant results. It is possible that in the Asian subgroup, the rs3775291 SNP was associated with cancer risks due to differences in genetic and environmental backgrounds between Asians and Caucasians. In the subgroup analyses, we found a significant association in the small sample size subgroup but not in the large sample size subgroup. In the large sample size subgroup, the ORs in the 5 included studies were all approximately 1.0, whereas the ORs in the studies conducted by Li *et al*. \[[@CR9]\], Zeljic *et al*. \[[@CR19]\], and Moumad *et al.* \[[@CR21]\] indicated a significant association in the small sample size subgroup. The same was true for the hospital-based analysis. Reliable results could be obtained in these cases based on the high quality of the studies designed to explore the real associations of *TLR3* SNPs with cancer risk. Differences in patients' genetic or environmental backgrounds might certainly be a common mechanism behind the conclusions of our stratification analysis. Differences in how studies were controlled or documented might also provide an explanation for these conclusions. For example, the studies conducted by Li *et al*. \[[@CR9]\] and Moumad *et al*. \[[@CR21]\] were well controlled, which might explain why positive results were obtained following the analysis of the small sample size subgroup. Furthermore, rs3775291 is located in exon 4, and the G to A variant results in the change of a leucine to phenylalanine at residue 412, which might provide a mechanistic explanation for the effects of this SNP.

Similar to rs5743312, rs3775292 is an intronic polymorphism that has also been investigated in detail, as its location in intron 3 is near rs3775290 and rs3775291. Thus, this polymorphism might be associated with variability in alternative splicing and further associated with the linkage disequilibrium between rs3775290 and rs3775291 \[[@CR24]\]. Two of the included studies showed no association of these SNPs with cancer risk, whereas one showed an association. However, our integrated meta-analysis results did not find any association between the rs3775292 SNP and cancer risk. Additional studies will be required to confirm these results.

Our meta-analysis had several limitations. First, only studies that were published in English or Chinese were included in our analysis, thereby creating potential publication bias. Second, the pooled sample size was relatively limited and therefore could support only preliminary evaluations of the association between various *TLR3* polymorphisms and the incidence of various types of cancer. Additionally, we were not always able to obtain original data from the published literature, such as the age and sex of the patients, or the environmental factors that might have affected the hosts. Thus, we used unadjusted information, whereas a more precise analysis could be conducted if detailed information on the original data were available. Therefore, additional studies are required to improve the reliability of these results.

Conclusion {#Sec13}
==========

In summary, this meta-analysis indicated that the variant allele of *TLR3* rs5743312 is potentially associated with increased cancer risks both in the whole collection of studies and in the large sample size subgroup. In the stratified analysis, the variant genotype of the *TLR3* rs3775290 polymorphism was associated with an increased cancer risk in the Asian subgroup. *TLR3* rs3775291 was also associated with an increased cancer risk in the Asian, hospital-based source of controls, and small sample size subgroups. No association was found between *TLR3* rs3775292 and cancer risk. Additional well-designed, large-scale, and functional studies on *TLR3* SNPs are required to confirm our findings.
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